Pharmacy
links with Zimbabwe
By
ELLEN GOLDBAUM
Contributing Editor
Improving
treatment of patients with HIV in Zimbabwe and potentially other developing
nations by adapting approaches that have been successful in the U.S.
is the goal of a new collaborative effort between UB and the University
of Zimbabwe.
About
25 percent of Zimbabwe's adult population is infected with HIV, according
to the United Nations.
A
primary goal of the program is to equip pharmacists at the University
of Zimbabwehome to the nation's only medical schoolwith
training and resources so that they can begin to conduct more clinical
pharmacology trials of AIDS drugs. UB's online HIV Pharmacotherapy Network
http://hiv.buffalo.edu also will
be utilized to encourage the global dissemination of ideas on HIV pharmacotherapy,
particularly as they pertain to developing nations.
With
new training and expertise, the University of Zimbabwe will be better
positioned to obtain funding from the World Health Organization to implement
pharmacology-related protocols and enroll patients in its own clinical
trials.
The
collaboration grew out of the relationship between the Department of
Pharmacy Practice in the School of Pharmacy and Pharmaceutical Sciences
and its chair, Gene Morse, with Chiedza Maponga, a 1988 graduate of
the school and a native of Zimbabwe.
"At
the moment, Zimbabwe lacks the resources and expertise to do advanced
clinical pharmacology and pharmacotherapeutic research on HIV, but an
extensive number of AIDS cases are there," explained Maponga. "That
is the patient population that is needed to conduct the studies and
work on this problem."
Morse
and Maponga stressed that the collaboration will be mutually beneficial
because through the exchange of research and education, it will provide
UB students and faculty with a critical international perspective on
AIDS.
"AIDS
is not just a national issue for the U.S., it's a global issue," said
Maponga. "Even from a business perspective, drug companies right now
are only concerned with the U.S. market, but there are fewer than 1
million people living with AIDS here, and about 28 million people with
AIDS living in sub-Saharan Africa. It is shortsighted to ignore that
huge market."
To
foster the collaboration, Maponga, who was the first Zimbabwean to earn
a doctorate of pharmacy and is now chair of the University of Zimbabwe's
Department of Pharmacy, has been funded as a visiting professor at UB
for two years by a National Institute for Allergy and Infectious Diseases
grant. The grant to UB supports Maponga's work in the Department of
Pharmacy Practice and its Laboratory for Antiviral Research, a Pharmacology
Support Laboratory for the National Institutes of Health Adult AIDS
Clinical Trials Group (AACTG) and a component of the AIDS Clinical Trials
Unit based at the University of Rochester.
Morse
has served as national chair of the Adult AIDS Clinical Trials Group
Pharmacology Committee of the NIH and under his direction, the UB lab
has developed methods to quantitatively and qualitatively analyze how
antiretrovirals, the main components of AIDS treatment, are metabolized,
and what their effectsboth beneficial and undesirableare
on patients.
According
to Morse, the Pharmacology Support Laboratory is an ideal environment
for providing integrated training in HIV pharmacotherapy.
"We
are one of a handful of places in the country that has an innovative
HIV Adherence-Pharmacology Program integrated with a larger laboratory
and clinical research initiative focused on AIDS pharmacology," said
Morse, who also is associate dean of clinical education and research
with the School of Pharmacy and Pharmaceutical Sciences. "There are
very few places in the U.S. in which so many different kinds of pharmacological
expertise are together in one place."
Morse
said the Pharmacology Support Lab has evolved a focus on both research
and education, including clinical practice and training in adherence
so patients stick to their regimens, and state-of-the-art laboratory
analysis to measure blood concentrations of AIDS drugs. In addition,
through expanded efforts in pharmacometrics, UB pharmacy faculty members
Alan Forrest, clinical professor, and Patrick Smith and Robert DiCenzo,
both clinical assistant professors, are providing innovative approaches
to interpreting pharmacology data.
While
the affordability of AIDS drugs remains a key concern for African nations,
Maponga said training in the U.S. has demonstrated to him that even
an enormous donation of drugs would not by itself solve the problem
in Zimbabwe.
"Here
in the U.S., you don't think about the cost of drugs, but you do highlight
the complexities of managing HIV and that is most important," he said.
"We
cannot fool ourselves into thinking that just getting the drugs is the
answer. In the whole AIDS equation, the cost of drugs contributes only
about 5 percent."
The
rest of the "equation," he continued, are the costs associated with
caring for AIDS patients, patient management, prevention of other infections,
caring for the sick at home, monitoring and treating drug resistance,
and adherence and compliance with complex drug regimens.
These
are in addition to the enormous social consequences to people with AIDS
and their families, particularly children who have been orphaned by
the disease.